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ABSTRACT 
Cerebral amyloid-beta (Aβ) deposition is a critical feature of Alzheimer’s disease. Aβ 
is derived from the amyloid precursor protein (AβPP) via two sequential cleavages 
that are mediated by beta-secretase and the gamma-secretase complex. Such 
amyloidogenic AβPP processing occurs in lipid raft microdomains of cell membranes 
and it is thought that modulating the distribution of lipids in rafts may regulate AβPP 
processing and Aβ production. Certain ATP-binding cassette (ABC) transporters 
regulate lipid transport across cell membranes and, as recent studies reveal, within 
membrane microdomains. ABCA1 also regulates Aβ metabolism in the brain 
although its direct impact on AβPP remains an open question. Here we assessed the 
capacity of three ABCA1 mutants (that do not promote lipid efflux) to modulate 
AβPP processing. Unexpectedly, these non-functional mutants also reduced Aβ 
production similar to wild type ABCA1. ABCA1 expression did not alter AβPP 
localization in lipid rafts, and co-immunoprecipitation experiments indicated ABCA1 
and AβPP physically interact. These data suggest that ABCA1 may regulate AβPP 
processing independent of its impact on membrane lipid homeostasis. 
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INTRODUCTION 
 
Several members of the ATP-binding cassette (ABC) transporter family regulate lipid 
transport across cell membranes [1,2]. ABCA1 is the most studied ABC transporter in 
the lipid homeostasis context; in part this is due to the discovery that loss of function 
mutations in the ABCA1 gene cause Tangier disease [3-5]. Tangier disease is 
characterised by severely impeded capacity for cells to efflux cholesterol and 
concomitant low levels of plasma high-density lipoprotein (HDL). These conditions 
result in cellular lipid accumulation and premature atherosclerosis. 
 
An important role for ABCA1 in the regulation of cholesterol transport in the brain 
has also been established. Cholesterol efflux from neurons is accelerated in the 
presence of lipid-poor apoA-I and apoE, and in vitro studies demonstrated that the 
function of these cholesterol acceptors is largely dependent on ABCA1 (reviewed in 
[6]). Astrocyte ABCA1 (and ABCG1) expression also plays an important role in apoE 
lipidation [7-9]. Studies in mice show that ABCA1-mediated lipidation of apoE in the 
brain regulates apoE turnover and this has important implications for the apoE-
dependent metabolism of amyloid-beta (Aβ) peptide; a neurotoxic and pro-
inflammatory peptide that impairs memory, and represents a major constituent of 
cerebral amyloid plaques in Alzheimer’s disease (AD) [10-13]. The direct role that 
ABCA1 might play in the modulation of neuronal amyloid precursor protein (AβPP) 
processing to generate Aβ remains an open question. 
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Previous studies have shown that over-expression of ABCA1 in neuronal and AβPP -
expressing non-neuronal cell lines resulted in an apparent inhibition of Aβ production 
[14,15]. Interestingly, this inhibition of Aβ production was observed in the absence of 
an extracellular cholesterol acceptor. It is thus unclear if ABCA1 cholesterol efflux 
activity is a functional prerequisite for its modulation of AβPP processing. Lipid raft 
microdomains are the major site for amyloidogenic processing of AβPP [16] and 
previous work has shown that depletion of membrane cholesterol reduces AβPP 
localisation in rafts [17]. This in turn inhibits AβPP proteolytic processing by β- and 
γ-secretase thereby suppressing Aβ production [17-19]. Based on the fact that 
ABCA1 not only stimulates cholesterol efflux across membranes to apolipoprotein 
acceptors (as mentioned above) but also promotes the lateral redistribution of 
cholesterol from lipid rafts to non-raft microdomains in membranes [20,21], it seems 
plausible that ABCA1 may influence AβPP processing via regulation of intra-
membrane cholesterol distribution and trafficking of AβPP to rafts. In line with this 
idea, the effect of ABCA1 on the lateral redistribution of membrane lipids out of rafts 
was shown to have a significant impact on the localisation of transferrin receptor 
(TfR) and toll-like receptor 4 (TLR4) in membrane microdomains of HeLa cells and 
macrophages, respectively [22,23]. 
 
In the present study we have assessed the impact that wild type and mutant ABCA1 
has on cellular Aβ production. We have also investigated the potential regulation of 
AβPP localisation in lipid rafts by ABCA1. Unexpectedly, wild type and three 
different ABCA1 mutants all suppressed cellular Aβ production and this was 
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independent of AβPP raft localisation. Co-immunoprecipitation experiments did 
however reveal an interaction between ABCA1 and AβPP that may contribute to 
suppression of cellular Aβ production. 
 
 
MATERIALS AND METHODS 
 
Materials 
Cell culture media and additives were obtained from Invitrogen (Melbourne, 
Australia) unless stated otherwise. Human wild type and mutant ABCA1 cDNA and 
expression plasmids were generated as described previously [24,25]. The CHO cell 
line stably expressing the human 695 amino acid AβPP (CHO-AβPP) was generated 
as described previously [26]. 
 
Cell Culture 
The SK-N-SH and HEK293 cell lines were obtained from the ATCC (Manassas, VA). 
Cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 
10% fetal calf serum (FCS), 2 mM glutamine, 100 IU/ml penicillin and 100 µg/ml 
streptomycin at 37°C in humidified air containing 5% CO2. HEK293 cells were grown 
on poly-D-lysine coated plates to ensure maximal adhesion. The CHO-AβPP cell line 
stably expressing the human 695 amino acid AβPP was maintained using zeocin (200 
µg/ml). Transfected cells were cultured in RPMI 1640 medium containing 10% FCS, 
2 mM glutamine and 100 IU/ml penicillin and 100 µg/ml streptomycin. 
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Transfection 
Transient transfection was performed using Lipofectamine 2000 and Opti-MEM I 
(Invitrogen) following the manufacturer’s protocol. Briefly, cells were seeded at 
approximately 90% confluency in 12 well plates using antibiotic-free medium. 
cDNA-Lipofectamine complex was added to the cells and after 24 h of incubation 
samples were collected for gene expression analysis. In the case of cholesterol efflux 
assays the cells were cultured for up to an additional 16 h.  
 
Cholesterol Efflux Assay 
Cellular cholesterol efflux was measured as described previously [27]. In brief, cells 
were labelled with 2 µCi/ml [3H]-cholesterol (Amersham Biosciences) for 16 h, 
rinsed with phosphate-buffered saline (PBS) and incubated for 2 h in medium 
containing 0.1% (w/v) bovine serum albumin (BSA) to allow equilibration of [3H]-
cholesterol in intracellular pools. The cells were rinsed once more in PBS and then 
incubated in serum-free medium containing 0.1% BSA with or without cholesterol 
acceptors for up to 16 h (i.e. 0.1% BSA is always present). Media samples were 
collected at the specified time point and cleared of any cellular debris by 
centrifugation at 1000 g for 5 min. The cells were lysed with 0.1 M NaOH and 
radioactivity in the media samples and cell lysates were measured by scintillation 
counting. Cholesterol effluxed to the medium was calculated as a percentage of total 
radioactivity in the cell lysates and medium. Experiments were performed in triplicate 
and repeated twice. Human apoA-I (15 µg / ml) was used as a cholesterol acceptor 
and was purified from human high-density lipoprotein (HDL) by ultracentrifugation 
and anion exchange chromatography as previously described [28]. 
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Western Blotting 
Cells expressing wild type or mutant ABCA1 and/or AβPP 695 were cultured in 6 
well plates, rinsed with cold PBS and lysed in lysis buffer (20 mM Tris–HCl, pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.5% deoxycholate, 0.1% SDS, and 
protease and phosphatase inhibitors). Bicinchoninic acid protein assays was 
performed on lysates and equal amounts of protein were separated on SDS-PAGE 
gels (6% acrylamide) and transferred onto 0.45 µm nitrocellulose membranes at 100 
volts for 30 min. Membranes were blocked overnight at 4°C in PBS containing 5% 
non-fat dry milk and probed with the relevant antibodies to reveal the major bands at 
the appropriate Mr: ABCA1 250 kDa (Novus, rabbit polyclonal 1/1000), AβPP 90 
kDa (Sigma, 6E10 monoclonal 1/2000) at 22˚C for 2 h. The membranes were washed 
three times in PBS containing 0.1% Tween-20 and then incubated with horseradish 
peroxidase-conjugated goat anti-rabbit (Dako, 1/2000) or rabbit anti-mouse (Dako, 
1/1000) secondary antibody for 2 h. Signals were detected using enhanced chemi-
luminescence (ECL, Amersham Biosciences) and X-ray films. The signal intensity 
was quantified using NIH ImageJ software. 
 
Western blotting of secreted Aβ peptides was carried out as previously described [15]. 
Briefly, Aβ in the culture medium was separated on 10–20% Tris/Tricine gels or 12% 
SDS-PAGE gels and transferred onto 0.2 µm nitrocellulose membranes at 65 volts for 
15 min. Membranes were boiled in milli-Q H2O for 10 min, probed with WO2 
monoclonal antibody followed by rabbit anti-mouse horseradish peroxidase-
conjugated secondary antibody and ECL detection applied as described above. AβPP 
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was also analysed by western blotting under non-reducing conditions. CHO-AβPP 
cells were homogenized in cold hypotonic buffer (250 mM sucrose, 10 mM HEPES, 
pH 7.4, 1 mM EDTA containing protease and phosphatase inhibitors) using 
microfuge tubes and tight pestles. The samples were centrifuged at 800 g for 20 min 
at 4°C, the supernatant mixed with SDS-free loading buffer and electrophoresed on 
Bis-Tris PAGE gels and analysed by western blotting as described above.  
 
Western blotting for cellular levels of the AβPP C-terminal fragment (CTFβ) was 
performed as described previously [29] using rabbit polyclonal antibody raised 
against C-terminal amino acids 676-695 of human AβPP695 (Sigma, Cat# A8717). 
Western blotting for cellular presenilin 1 (PS1), BACE1 and nicastrin was performed 
as described previously [30,31] using in-house antibodies 98/1 and 00/5 for PS1 and 
BACE1, respectively, and a commercial antibody (Sigma, Cat # N-1660) for 
nicastrin. 
 
Quantitative real-time PCR 
RNA was isolated from cells using TRIzol reagent (Invitrogen) following the 
manufacturer’s protocol. All procedures were carried out using RNase-free reagents. 
Four µg of RNA was reverse transcribed into cDNA as previously described [32]. 
cDNA was used as a template in the quantitative real-time PCR assay, which was 
carried out using a Mastercycler ep realplex S (Eppendorf) and the fluorescent dye 
SYBR Green (Eppendorf), following the manufacturer’s protocol. Briefly, each 
reaction (20 µl) contained 1x RealMasterMix, 1x SYBR green, 5 pmoles of primers 
and 1 µl of template. Amplification was carried out with 40 cycles of 94°C for 15 sec 
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and 60°C for 1 min. All gene expression was normalized to β-actin, which served as 
an internal control for the quality of RNA isolated from each cell sample. 
Experiments were performed in triplicate and at least three samples were analysed for 
each cell type. Conventional PCR amplification was also carried out with 30 cycles of 
denaturation (94°C, 30 s), annealing (60°C, 30 s) and extension (72°C, 30 s), and the 
PCR products were visualized after electrophoresis in 1% agarose gels. Details of all 
primers used are provided as Supplementary Data (Supplementary Table 1). 
 
 
Preparation of cell membrane lipid raft fractions 
Lipid raft and non-raft fractions were prepared from CHO-AβPP and SK-N-SH cells 
as described previously [33]. Briefly, confluent cells grown in 175 cm2 flasks were 
rinsed twice with phosphate buffered saline (PBS), resuspended in Buffer M (50 mM 
HEPES pH 7.4, 10 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA plus protease inhibitor 
cocktail (Complete Mini, Roche Applied Science), 1 mM Na3VO4, 1 mM NaF and 1 
mM Na4P2O7.10 dH2O) and homogenized in microfuge tubes using tight pestles 
(Sigma, Castle Hill, NSW, Australia) while on ice. The cell lysates were centrifuged 
at 16,000 g for 20 min at 4°C. The pellets were resuspended in Buffer A (25 mM 2-
(N-morpholino)-ethanesulfonic acid, 150 mM NaCl, pH 6.5) and mixed with an equal 
volume of Buffer A containing 2% Triton X-100 and phosphatase and protease 
inhibitors. The samples were kept on ice for 60 min, centrifuged at 16,000 g for 20 
min at 4°C and the supernatants collected as non-raft fraction. The pellets were rinsed 
briefly with Buffer A and resuspended in Buffer B (10 mM Tris-Cl, pH 7.6, 150 mM 
NaCl, 60 mM β-octylglucoside and phosphatase and protease inhibitors). The samples 
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were kept on ice for 30 min, centrifuged at 16,000 g for 20 min at 4°C and the 
supernatants collected as the lipid raft fraction. 
 
Immunoprecipitation 
Immunoprecipitation of ABCA1 was carried out as described previously [34]. Briefly, 
CHO-AβPP cells were rinsed once with cold PBS, resuspended in homogenization 
buffer (100 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Triton X-100 plus protease 
inhibitor cocktail), homogenized in microfuge tubes using tight pestles while on ice, 
and cell lysates collected after centrifugation at 1,000 g for 10 min at 4°C. The cell 
lysates were mixed (in rotation) with the anti-AβPP antibody WO2 and Protein G 
Sepharose beads (Sigma, cat# P3296) at 4°C overnight, and then washed three times 
in the homogenization buffer and analysed by western blotting as described above. 
 
Quantification of Aβ1-40 by ELISA 
The concentration of Aβ1-40 in cell culture supernatants was determined using 
ELISA kits (BioSource International) following the manufacturer’s instructions. 
Culture supernatants were diluted 1:10 in 55 mM NaHCO3 (pH 9.0) and all standards 
and samples were assayed in triplicate. 
 
Statistical Analysis 
Experiments were routinely performed in triplicate and repeated three times. Data are 
presented as means with SE shown by error bars. Differences were considered 
significant where p < 0.05 as determined by the 2-tailed Student’s t-test for unpaired 
data. 
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RESULTS 
 
In previous studies we have shown that in the absence of an extracellular acceptor to 
stimulate cholesterol efflux, ABCA1 expression significantly reduced cellular Aβ 
production [15]. This suggested that ABCA1-dependent removal of cholesterol from 
cell membranes was not a strict requirement for modulation of AβPP processing. In 
order to investigate the impact that non-functional ABCA1 mutants may have on 
cellular AβPP processing and Aβ production we first verified the loss of cholesterol 
efflux function in two ABCA1 mutants (R587W and W590S) associated with Tangier 
disease and an additional mutant in which the C-terminal 46 amino acids (Δ46) have 
been deleted (Fig 1A). Transient transfection of HEK293 cells resulted in similar 
levels of both mRNA and protein for WT and mutant ABCA1 cDNAs (data not 
shown). Consistent with previous studies [24,25], apoA-I mediated cholesterol efflux 
was strongly induced by WT ABCA1, weakly induced by ABCA1W590S and not 
induced by either ABCA1R587W or ABCA1Δ46 expression as compared to mock 
transfected cells (Fig 1B). The loss of ABCA1 function in the mutants was previously 
ascribed to the variations in ABCA1 cell surface expression and apoA-I binding as 
summarised in Figure 1C. 
 
We next examined the potential for both WT and mutant ABCA1 to modulate AβPP 
processing in CHO-AβPP cells. Transient transfection of CHO-AβPP cells resulted in 
similar levels of both mRNA and protein for WT and mutant ABCA1 (Fig 2A-C). 
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Transfection of CHO-AβPP cells did not alter the expression of the housekeeper gene 
β-actin at either mRNA or protein levels (Fig 2A-C), nor did it affect the expression 
of the stably transfected human AβPP695 cDNA at the mRNA level (Fig 2A). 
Western blot analysis revealed that transfection of CHO-AβPP cells with either WT 
ABCA1 or the ABCA1R587W and ABCA1W590S mutants increased the level of AβPP 
detected at the protein level by 11% to 25% (Fig 2D-E), whereas levels of sAβPPα 
detected in the culture medium were not altered by transfection with any of the 
ABCA1 constructs as compared to the mock-transfected conditions (Fig 2D-E). These 
data suggest that the processing of AβPP via the non-amyloidogenic α-secretase 
pathway is not substantially altered by expression of either WT or mutant ABCA1. 
 
To gain insight into the potential modulation of AβPP processing via the 
amyloidogenic β- and γ-secretase pathway, we used additional techniques to quantify 
levels of the cellular C-terminal fragment (CTF) product of AβPP β-secretase 
processing (CTFβ) as well as extracellular levels of Aβ. The data derived from 
western blot analysis indicate that transient expression with either WT or mutant 
ABCA1 resulted in an increase in CTFβ and a decrease in secreted Aβ levels (Fig 3). 
The magnitude of increased CTFβ varied depending on the ABCA1 construct used; 
with the WT and ABCA1Δ46 mutant increasing CTFβ levels by ~2.5 fold, and the 
ABCA1R587W and ABCA1W509S mutants increasing CTFβ levels by ~2-fold and 25%, 
respectively (Fig 3B and D). In contrast, levels of extracellular Aβ peptide were 
significantly decreased by both WT and mutant ABCA1 transfection by a similar 
degree (36% to 45% on average, Fig 3B and D). This pattern of increased cellular 
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CTFβ level associated with decreased extracellular Aβ in ABCA1-transfected cells 
could theoretically be due to a decrease in γ-secretase activity or possibly a change in 
AβPP trafficking that results in its reduced localisation in lipid rafts. Since we have 
previously shown that the close relative of ABCA1, ABCA7, inhibits CHO-AβPP cell 
Aβ production independent of effects on either α-, β- or γ-secretase activities [35], we 
focused on the impact that ABCA1 expression has on AβPP localisation in lipid rafts. 
 
The methodology for lipid raft isolation requires scaling up of the cell culture system. 
Our first experiments therefore aimed to confirm that transient expression of ABCA1 
in 175 cm2 flasks resulted in the predicted inhibition of cellular Aβ production. 
Because the WT and three ABCA1 mutants all inhibited Aβ generation to a similar 
degree (Fig 3), we also limited this phase of the study to the WT ABCA1. Our data 
indicated that ABCA1 transfection of CHO-AβPP cells in the scaled-up cell culture 
system resulted in reduced extracellular Aβ levels to approximately the same extent 
observed when cluster plates were used for cell culture (Fig 4A cf Fig 3A and C). The 
decrease in Aβ levels in the cell culture medium was also confirmed by ELISA 
analysis of Aβ1-40 (mock 1.66 + 0.10 ng/ml vs ABCA1 1.02 + 0.04 ng/ml, mean + 
SE, n=4, p = 0.02); the predominant Aβ species produced by the CHO-AβPP cell line. 
 
We then isolated lipid raft and non-raft membrane fractions according to an 
established method [33]. Flotillin-2 and calnexin were used as markers to confirm the 
purity of the non-raft and raft fractions, respectively. As expected, flotilin-2 was 
highly enriched in rafts whereas calnexin was exclusively located in the non-raft 
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fraction (Fig 4B). When CHO-AβPP cells were transfected with ABCA1, we detected 
the vast majority (85% to 90%) of ABCA1 protein in the non-raft domains of the 
membranes as assessed after equal total protein loading of each of the fractions onto 
the gels (Supplementary Fig 1). Interestingly, ABCA1 was detected as a doublet band 
(which is known to be due to glycosylation heterogeneity [36]), and there was a clear 
preferential distribution of the higher molecular weight band in lipid rafts (Fig 4C and 
D, Supplementary Fig 1). A faint ABCA1 band was also detected in the non-raft 
fraction of mock-transfected cells, presumably as a result of cross-reaction of the 
antibody with hamster ABCA1 (Fig 4C, Supplementary Fig 1). Similarly, most 
(~80%) AβPP was located in non-raft fractions of both mock- and ABCA1-
transfected CHO-AβPP cells (Supplementary Fig 1). Importantly, AβPP levels in 
either raft or non-raft fractions were not significantly altered by transfection with 
ABCA1 (Fig 4C to E), although trends for reduced levels of AβPP and flotilin-2 in 
rafts were detected (Fig 4E). It should be noted that in order to compare protein 
expression levels by western blotting, ~8-fold more protein was loaded on gels 
assessing the lipid raft proteins as compared to non-raft proteins (i.e. panels in Fig 4C 
and 4D can not be directly compared to each other). These data indicate that despite 
an ~15-fold up-regulation of ABCA1 protein levels in both lipid raft and non-raft 
fractions, the relative amount of AβPP localised to lipid rafts was not significantly 
altered. We also considered the possibility that ABCA1 expression may reduce 
cellular levels of γ-secretase components or BACE1, however, levels of PS1, nicastrin 
and BACE1 were unaltered in whole cell lysates transfected with ABCA1 as 
compared to mock conditions (Suppl Fig 3). In addition, we could find no evidence 
that ABCA1 altered PS1 levels in lipid rafts. Intriguingly, ABCA1 transfection 
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increased nicastrin levels in lipid rafts by ~40%, whereas BACE1 levels were not 
reliably detected in rafts under our experimental conditions (Suppl Fig 3).  
 
Modulation of intramembrane AβPP trafficking therefore does not appear to be the 
mechanism by which ABCA1 down-regulates cellular Aβ production. One possible 
caveat in this conclusion is that the CHO-AβPP cells express a large amount of AβPP 
in a cell type that would not normally express this protein and thus subtle changes in 
AβPP trafficking may not be detected in this system. We therefore extended the study 
to assess the impact that ABCA1 has on endogenous AβPP processing and Aβ 
production in the human SK-N-SH neuroblastoma cell line. The levels of endogenous 
Aβ secreted into the cell culture medium is at least two orders of magnitude less than 
observed using the CHO-AβPP cell line. Cell culture medium was therefore 
concentrated approximately 10-fold before analysis of Aβ by western blotting and 
ELISA techniques. We used the same scaled-up culture methods that were used for 
the CHO-AβPP cell experiments to transfect SK-N-SH neurons in 175 cm2 flasks. 
The western blot data indicate that ABCA1 transfection reduced Aβ production by 
32% (p < 0.05). Three higher molecular weight species of Aβ were also detected by 
western blotting of SK-N-SH culture medium (Fig 5A) that may represent Aβ 
oligomers (although we cannot the possibility that these bands may represent as yet 
uncharacterised small AβPP proteolytic fragments). The levels of all these putative 
oligomeric forms of Aβ were also significantly reduced by ABCA1 transfection (p-
values for the three arrowed bands all <0.05 for mock versus ABCA1-transfected 
cells). These results were confirmed by ELISA analysis of Aβ1-40 in the concentrated 
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media samples (mock 0.182 + 0.010 ng/ml vs ABCA1 0.132 + 0.008 ng/ml, mean + 
SE, n=4, p < 0.05). 
 
It was not possible to quantify sAβPPα in the concentrated SK-N-SH supernatants as 
the western blot was signal was over-loaded (in order to allow Aβ detection), 
however, blotting of non-concentrated samples indicated neuronal sAβPPα 
production was not influenced by ABCA1 transfection (Supplementary Figure 2). 
 
Flotillin-2 was not reliably detected in the SK-N-SH cells so we used another 
established raft marker, Gαi-2 [33], in these experiments. Gαi-2 was exclusively 
located in rafts whereas calnexin was exclusively located in the non-raft fraction (Fig 
5B). ABCA1 was also exclusively detected in the non-raft domains of SK-N-SH 
membranes under both mock- and ABCA1-transfected conditions (Fig 5C and 5D). 
Similar to what was observed with CHO-AβPP cells, most AβPP (~90%) was located 
in non-raft fractions of both mock- and ABCA1-transfected SK-N-SH neurons (data 
not shown). Interestingly, AβPP levels were slightly, but significantly, increased in 
the lipid raft fraction of ABCA1-transfected cells, whereas a trend for a reduced level 
of the raft marker Gαi-2 was detected (Fig 5D and 5E). These data provide two 
important pieces of information. Firstly, the results highlight the fact that protein 
distribution in lipid rafts can vary depending on cell type (which in turn may be 
related to either the heterogeneity in the total complement of raft proteins in different 
cell types or due to differences in membrane lipid composition); and secondly, the 
results indicate that despite a 6.5-fold up-regulation of ABCA1 in the transfected 
neurons, the relative amount of AβPP localised to lipid rafts was not reduced (in fact 
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there was a slight increase). Therefore an inhibition of AβPP trafficking to lipid rafts 
does not appear to be the mechanism by which ABCA1 down-regulates neuronal Aβ 
production. 
 
Our findings that ABCA1 inhibits Aβ production via mechanisms that are not 
dependent on cholesterol efflux or modulation of AβPP localisation in lipid rafts led 
us to consider other pathways by which WT and mutant ABCA1 may have an impact 
on AβPP metabolism. Recent studies have shown that AβPP dimerisation inhibits its 
processing by γ-secretase thereby resulting in decreased Aβ production [37]. Using 
previously established PAGE conditions we analysed AβPP under non-reducing 
conditions and confirmed the presence of AβPP dimers in CHO-AβPP cell lysates 
(Fig 6A). However, transfection of CHO-AβPP cells with WT or mutant ABCA1 had 
no impact on the proportion of AβPP detected as dimers (Fig 6A); indicating that this 
is unlikely to contribute to the mechanism by which ABCA1 inhibits Aβ production. 
 
A large body of research indicates that AβPP interacts with several membrane and 
adapter proteins and that this can alter its processing by secretases as well as have an 
important impact on AβPP trafficking and degradation [38-45]. A previous proteomic 
analysis of ABCA1 binding partners identified more than 200 interacting proteins, 76 
of which specifically interacted with the C-terminal 40 amino acid region of ABCA1 
[46]. Intriguingly, co-immunoprecipitation studies utilising human IMR-32 
neuroblastoma cells or transfected HEK293 cells suggest a direct interaction between 
ABCA1 and AβPP695 [34]. In a final series of experiments we therefore used a co-
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immunoprecipitation approach to assess whether ABCA1 mutants also interact with 
AβPP. Our data indicate that ABCA1 co-purifies with immunoprecipitated AβPP in 
CHO-AβPP cells transfected with either WT or mutant ABCA1 but not in mock-
transfected cells (Fig 6B). 
 
DISCUSSION 
 
This study shows for the first time that WT ABCA1 and three non-functional ABCA1 
mutants all suppress cellular Aβ production by pathways that are associated with a 
moderate accumulation of AβPP CTFβ (e.g. compared to the pronounced 
accumulation of CTFβ that results when γ-secretase inhibitors are used to suppress 
Aβ production in CHO-AβPP cell lines [29]). It is established that removal of 
cholesterol from lipid rafts inhibits the amyloidogenic processing of AβPP and this 
results in decreased production of Aβ [17,47,48]. Other raft lipids, such as 
glycosphingolipids (GSLs), also modulate AβPP processing [29,49]. The mechanisms 
by which membrane lipid composition regulates Aβ generation may involve control 
of AβPP translocation to rafts, modulation of clathrin-dependent AβPP endocytosis, 
as well as direct regulation of β- and γ-secretase function [48-52]. Based on previous 
work indicating that ABCA1 inhibits Aβ generation in vitro and also promotes the 
removal of cholesterol from lipid rafts to non-raft domains, we speculated that 
ABCA1-mediated changes in membrane lipid composition could account for its anti-
amyloidogenic action. Unexpectedly, however, we found that non-functional ABCA1 
mutants also suppressed cellular Aβ production and that transient transfection of both 
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CHO-AβPP cells and SK-N-SH neurons with ABCA1 did not alter the proportion of 
AβPP localised to lipid rafts. This indicates that the pathway by which ABCA1 
influences AβPP processing is not related to modulation of AβPP localisation in lipid 
rafts, nor is it likely to be dependent on ABCA1 lipid transport function (particularly 
as assessed in the present study using cholesterol efflux to the amphipathic apoA-I 
acceptor protein). It is also unlikely that the inhibition of AβPP amyloidogenic 
processing is simply due to the over-expression of a large multi-transmembrane 
protein as we have previously shown that robust expression of ABCA2 (46% 
homologous to ABCA1) in CHO-AβPP cells has no impact on AβPP proteolytic 
processing or Aβ production [15]. Interestingly, studies by Chen et al. indicated that 
ABCA2 increased both AβPP expression and Aβ production in 293 EBNA cells 
stably transfected with AβPP695 whereas a similar sized control ABC transporter (not 
described in detail) had no impact on either AβPP expression or Aβ production [53]. 
Clearly, not all ABC transporters / large multi-transmembrane proteins inhibit AβPP 
amyloidogenic processing. 
 
Independent of effects on membrane lipid transport, several membrane proteins that 
interact with AβPP either directly or through adaptor proteins can inhibit (e.g. SorLA, 
X11 proteins) or promote (e.g. LRP, flotillin-2) amyloidogenic processing of AβPP 
[39,40,42-44,54] and there is increasing evidence that these types of interactions can 
modulate AβPP localisation to rafts or to subcellular compartments that alter the 
proteolytic processing of AβPP due factors such as reduced pH and colocalisation 
with secretase components [55-57]. As noted above, ABCA1 also interacts with a 
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large number of proteins and a direct interaction between ABCA1 and AβPP695 has 
been reported [34,46]. The molecular basis for this interaction (which was confirmed 
by our present study) remains uncertain. Using a human macrophage proteomics 
approach, 76 proteins were found to bind to the C-terminal 40 amino acids of ABCA1 
[46]. Interestingly, ABCA1 the ABCA1 C-terminal region was found to interact with 
nicastrin, an essential component of the γ-secretase complex that is required for γ-
secretase activity and for its function as a regulator of AβPP trafficking [46,58]. 
Whether nicastrin represents an intermediate binding protein for the ABCA1-AβPP 
interaction is unclear. The fact that ABCA1Δ46 interacts with AβPP (albeit at lower 
levels than for the WT and other ABCA1 mutants, see Fig 6B) suggests that the C-
terminal region is not essential for interaction with AβPP. In the case of the SorLA-
AβPP interaction, it is the extracellular carbohydrate-linked domain of AβPP that is 
crucial [42]. Given that both AβPP and ABCA1 bind multiple membrane and adaptor 
proteins, it seems reasonable to conclude that there may be more than one type of 
interaction linking these proteins and this may be dependent on the cell type, 
membrane composition and subcellular location. 
 
The current data should also be considered in terms of possible cell-specific functions 
that ABCA1 may play related to Aβ homeostasis. There is compelling evidence that 
astrocyte ABCA1 plays a role in the lipidation of apoE and that this in turn regulates 
Aβ uptake and metabolism [7,59-61]. In addition to astroglia, neurons also express 
ABCA1 (reviewed in [6]) and data from postmortem tissue indicate ABCA1 
immunostaining in human CA1 hippocampal neurons is significantly up-regulated in 
AD [62]. We speculate that neuronal ABCA1 may be up-regulated in response to 
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changes that occur in AD tissue in an attempt to limit further Aβ production. Previous 
studies have shown that even in the absence of extracellular apoE to promote 
cholesterol efflux from the cell membrane, ABCA1 transfection still has the capacity 
to reduce extracellular Aβ levels in vitro [15]. This earlier finding is consistent with 
our current data indicating that loss-of-function mutations do not prevent this apparent 
direct anti-amyloidogenic action of ABCA1. We speculate that astroglial and 
neuronal ABCA1 may act in concert, possibly via different pathways, to reduce the 
accumulation of Aβ in the brain. 
 
In conclusion, our data indicate that the mechanisms underlying the inhibitory effect 
that ABCA1 has on amyloidogenc AβPP processing are independent of its lipid 
transporter function and do not appear to be related to changes in AβPP raft 
localisation. 
 
ACKNOWLEDGEMENTS 
We are grateful to Prof Kerry-Anne Rye for provision of human apoA-I, to Prof Colin 
Masters and Dr Qiao-Xin Li for providing WO2 antibody, and to Dr Janetta Culvenor 
for providing 98/1 antibody. This work was supported by the National Health and 
Medical Research Council of Australia (NHMRC Grant No. 510148). Prof Garner is 
supported by a Fellowship from the Australian Research Council (FT0991986). 
 
 
REFERENCES 
 
 23 
[1] Schmitz G, Kaminski WE, Orso E (2000) ABC transporters in cellular lipid 
trafficking. Curr Opin Lipidol 11, 493-501. 
[2] Kaminski WE, Piehler A, Wenzel JJ (2006) ABC A-subfamily transporters: 
structure, function and disease. Biochim Biophys Acta 1762, 510-524. 
[3] Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, 
Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, 
Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G (1999) 
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier 
disease. Nat Genet 22, 347-351. 
[4] Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu 
L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, 
Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale 
D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J, Jr., 
Hayden MR (1999) Mutations in ABC1 in Tangier disease and familial high-
density lipoprotein deficiency. Nat Genet 22, 336-345. 
[5] Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer 
JJ, Vaughan AM, Oram JF (1999) The Tangier disease gene product ABC1 
controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin 
Invest 104, R25-31. 
[6] Kim WS, Weickert CS, Garner B (2008) Role of ATP-binding cassette 
transporters in brain lipid transport and neurological disease. J Neurochem 
104, 1145-1166. 
[7] Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski 
BA, DeKosky ST, Lazo JS (2003) 22R-hydroxycholesterol and 9-cis-retinoic 
 24 
acid induce ATP-binding cassette transporter A1 expression and cholesterol 
efflux in brain cells and decrease amyloid beta secretion. J Biol Chem 278, 
13244-13256. 
[8] Karten B, Campenot RB, Vance DE, Vance JE (2006) Expression of ABCG1, 
but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J 
Biol Chem 281, 4049-4057. 
[9] Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, 
Ramaekers FC, de Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M 
(2006) 24(S)-hydroxycholesterol participates in a liver X receptor-controlled 
pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol 
efflux. J Biol Chem 281, 12799-12808. 
[10] Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related 
changes. Acta Neuropathol (Berl) 82, 239-259. 
[11] Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 
487-498. 
[12] Barger SW, Harmon AD (1997) Microglial activation by Alzheimer amyloid 
precursor protein and modulation by apolipoprotein E. Nature 388, 878-881. 
[13] Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, 
Ashe KH (2006) A specific amyloid-beta protein assembly in the brain 
impairs memory. Nature 440, 352-357. 
[14] Sun Y, Yao J, Kim TW, Tall AR (2003) Expression of liver X receptor target 
genes decreases cellular amyloid beta peptide secretion. J Biol Chem 278, 
27688-27694. 
 25 
[15] Kim WS, Suryo Rahmanto A, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, 
Jessup W, Hill AF, Garner B (2007) Role of ABCG1 and ABCA1 in 
regulation of neuronal cholesterol efflux to apolipoprotein-E discs and 
suppression of amyloid-beta peptide generation. J Biol Chem 282, 2851-2861. 
[16] Vetrivel KS, Thinakaran G (2010) Membrane rafts in Alzheimer's disease 
beta-amyloid production. Biochim Biophys Acta 1801, 860-867. 
[17] Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K 
(1998) Cholesterol depletion inhibits the generation of beta-amyloid in 
hippocampal neurons. Proc Natl Acad Sci U S A 95, 6460-6464. 
[18] Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, 
Hartmann T (2002) Inhibition of intracellular cholesterol transport alters 
presenilin localization and amyloid precursor protein processing in neuronal 
cells. J Neurosci 22, 1679-1689. 
[19] Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, 
Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of 
Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. 
Nature 325, 733-736. 
[20] Landry YD, Denis M, Nandi S, Bell S, Vaughan AM, Zha X (2006) ABCA1 
expression disrupts raft membrane microdomains through its ATPase-related 
functions. J Biol Chem 281, 36091-36101. 
[21] Vaughan AM, Oram JF (2003) ABCA1 redistributes membrane cholesterol 
independent of apolipoprotein interactions. J Lipid Res 44, 1373-1380. 
[22] Zarubica A, Plazzo AP, Stockl M, Trombik T, Hamon Y, Muller P, Pomorski 
T, Herrmann A, Chimini G (2009) Functional implications of the influence of 
 26 
ABCA1 on lipid microenvironment at the plasma membrane: a biophysical 
study. FASEB J 23, 1775-1785. 
[23] Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, Hiltbold EM, 
Fessler MB, Parks JS (2010) Macrophage ABCA1 reduces MyD88 dependent 
toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. 
J Lipid Res 51, 3196-3206. 
[24] Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman 
MW (2002) Naturally occurring mutations in the largest extracellular loops of 
ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 
277, 33178-33187. 
[25] Fitzgerald ML, Okuhira K, Short GF, 3rd, Manning JJ, Bell SA, Freeman MW 
(2004) ATP-binding cassette transporter A1 contains a novel C-terminal 
VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding 
activities. J Biol Chem 279, 48477-48485. 
[26] White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke 
DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush 
AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-
peptide by metal-dependent up-regulation of metalloprotease activity. J Biol 
Chem 281, 17670-17680. 
[27] Glaros EN, Kim WS, Quinn CM, Wong J, Gelissen I, Jessup W, Garner B 
(2005) Glycosphingolipid accumulation inhibits cholesterol efflux via the 
ABCA1 / apoA-I pathway. 1-Phenyl-2-Decanoylamino-3-Morpholino-1-
Propanol is a novel cholesterol efflux accelerator. J Biol Chem 280, 24515-
24523. 
 27 
[28] Rye KA, Garrety KH, Barter PJ (1993) Preparation and characterization of 
spheroidal, reconstituted high-density lipoproteins with apolipoprotein A-I 
only or with apolipoprotein A-I and A-II. Biochim Biophys Acta 1167, 316-
325. 
[29] Li H, Kim WS, Guilemin GJ, Hill AF, Evin G, Garner B (2010) Modulation of 
amyloid precursor protein processing by synthetic ceramide analogues. 
Biochim Biophys Acta 1801, 887-895. 
[30] Sharples RA, Vella LJ, Nisbet RM, Naylor R, Perez K, Barnham KJ, Masters 
CL, Hill AF (2008) Inhibition of gamma-secretase causes increased secretion 
of amyloid precursor protein C-terminal fragments in association with 
exosomes. FASEB J 22, 1469-1478. 
[31] Santosa C, Rasche S, Barakat A, Bellingham SA, Ho M, Tan J, Hill AF, 
Masters CL, McLean C, Evin G (2011) Decreased expression of GGA3 
Protein in Alzheimer's disease frontal cortex and increased co-distribution of 
BACE with the amyloid precursor protein. Neurobiol Dis 43, 176-183. 
[32] Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B (2006) Quantitation of 
ATP-binding cassette subfamily-A transporter gene expression in primary 
human brain cells. Neuroreport 17, 891-896. 
[33] Adam RM, Yang W, Di Vizio D, Mukhopadhyay NK, Steen H (2008) Rapid 
preparation of nuclei-depleted detergent-resistant membrane fractions suitable 
for proteomics analysis. BMC Cell Biol 9, 30. 
[34] Umeda T, Mori H, Zheng H, Tomiyama T (2010) Regulation of cholesterol 
efflux by amyloid beta secretion. J Neurosci Res 88, 1985-1994. 
 28 
[35] Chan SL, Kim WS, Kwok JB, Hill AF, Cappai R, Rye KA, Garner B (2008) 
ATP-binding cassette transporter A7 regulates processing of amyloid 
precursor protein in vitro. J Neurochem 106, 793-804. 
[36] Tanaka AR, Abe-Dohmae S, Ohnishi T, Aoki R, Morinaga G, Okuhira K, 
Ikeda Y, Kano F, Matsuo M, Kioka N, Amachi T, Murata M, Yokoyama S, 
Ueda K (2003) Effects of mutations of ABCA1 in the first extracellular 
domain on subcellular trafficking and ATP binding/hydrolysis. J Biol Chem 
278, 8815-8819. 
[37] Eggert S, Midthune B, Cottrell B, Koo EH (2009) Induced dimerization of the 
amyloid precursor protein leads to decreased amyloid-beta protein production. 
J Biol Chem 284, 28943-28952. 
[38] Trommsdorff M, Borg JP, Margolis B, Herz J (1998) Interaction of cytosolic 
adaptor proteins with neuronal apolipoprotein E receptors and the amyloid 
precursor protein. J Biol Chem 273, 33556-33560. 
[39] Tomita S, Fujita T, Kirino Y, Suzuki T (2000) PDZ domain-dependent 
suppression of NF-kappaB/p65-induced Abeta42 production by a neuron-
specific X11-like protein. J Biol Chem 275, 13056-13060. 
[40] Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH (2002) The 
cytoplasmic domain of the LDL receptor-related protein regulates multiple 
steps in APP processing. EMBO J 21, 5691-5700. 
[41] Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH (2003) 
Proteasome-mediated degradation of the C-terminus of the Alzheimer's 
disease beta-amyloid protein precursor: effect of C-terminal truncation on 
production of beta-amyloid protein. J Neurosci Res 74, 378-385. 
 29 
[42] Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, 
McKinstry WJ, Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE 
(2006) Molecular dissection of the interaction between amyloid precursor 
protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 
(Mosc) 45, 2618-2628. 
[43] Suzuki T, Nakaya T (2008) Regulation of amyloid beta-protein precursor by 
phosphorylation and protein interactions. J Biol Chem 283, 29633-29637. 
[44] Bu G, Cam J, Zerbinatti C (2006) LRP in amyloid-beta production and 
metabolism. Ann N Y Acad Sci 1086, 35-53. 
[45] Bai Y, Markham K, Chen F, Weerasekera R, Watts J, Horne P, Wakutani Y, 
Bagshaw R, Mathews PM, Fraser PE, Westaway D, St George-Hyslop P, 
Schmitt-Ulms G (2008) The in vivo brain interactome of the amyloid 
precursor protein. Mol Cell Proteomics 7, 15-34. 
[46] Okuhira K, Fitzgerald ML, Sarracino DA, Manning JJ, Bell SA, Goss JL, 
Freeman MW (2005) Purification of ATP-binding cassette transporter A1 and 
associated binding proteins reveals the importance of beta1-syntrophin in 
cholesterol efflux. J Biol Chem 280, 39653-39664. 
[47] Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic 
processing of the Alzheimer beta-amyloid precursor protein depends on lipid 
rafts. J Cell Biol 160, 113-123. 
[48] Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, 
Thinakaran G (2005) Spatial segregation of gamma-secretase and substrates in 
distinct membrane domains. J Biol Chem 280, 25892-25900. 
 30 
[49] Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, 
Simons K (2005) Lipids as modulators of proteolytic activity of BACE: 
involvement of cholesterol, glycosphingolipids, and anionic phospholipids in 
vitro. J Biol Chem 280, 36815-36823. 
[50] Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ (2008) Direct and 
potent regulation of gamma-secretase by its lipid microenvironment. J Biol 
Chem 283, 22529-22540. 
[51] Cossec JC, Marquer C, Panchal M, Lazar AN, Duyckaerts C, Potier MC 
(2010) Cholesterol changes in Alzheimer's disease: methods of analysis and 
impact on the formation of enlarged endosomes. Biochim Biophys Acta 1801, 
839-845. 
[52] Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J, 
Duyckaerts C, Lenkei Z, Potier MC (2010) Clathrin-dependent APP 
endocytosis and Abeta secretion are highly sensitive to the level of plasma 
membrane cholesterol. Biochim Biophys Acta 1801, 846-852. 
[53] Chen ZJ, Vulevic B, Ile KE, Soulika A, Davis W, Jr., Reiner PB, Connop BP, 
Nathwani P, Trojanowski JQ, Tew KD (2004) Association of ABCA2 
expression with determinants of Alzheimer's disease. FASEB J 18, 1129-1131. 
[54] Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, 
Strickland DK (2000) Modulation of beta-amyloid precursor protein 
processing by the low density lipoprotein receptor-related protein (LRP). 
Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J 
Biol Chem 275, 7410-7415. 
 31 
[55] Miller CC, McLoughlin DM, Lau KF, Tennant ME, Rogelj B (2006) The X11 
proteins, Abeta production and Alzheimer's disease. Trends Neurosci 29, 280-
285. 
[56] Schneider A, Rajendran L, Honsho M, Gralle M, Donnert G, Wouters F, Hell 
SW, Simons M (2008) Flotillin-dependent clustering of the amyloid precursor 
protein regulates its endocytosis and amyloidogenic processing in neurons. J 
Neurosci 28, 2874-2882. 
[57] Saito Y, Sano Y, Vassar R, Gandy S, Nakaya T, Yamamoto T, Suzuki T 
(2008) X11 proteins regulate the translocation of amyloid beta-protein 
precursor (APP) into detergent-resistant membrane and suppress the 
amyloidogenic cleavage of APP by beta-site-cleaving enzyme in brain. J Biol 
Chem 283, 35763-35771. 
[58] Li T, Ma G, Cai H, Price DL, Wong PC (2003) Nicastrin is required for 
assembly of presenilin/gamma-secretase complexes to mediate Notch 
signaling and for processing and trafficking of beta-amyloid precursor protein 
in mammals. J Neurosci 23, 3272-3277. 
[59] Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, 
Kowalewski T, Holtzman DM (2004) ABCA1 is required for normal central 
nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J 
Biol Chem 279, 40987-40993. 
[60] Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, 
Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, 
Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes 
the proteolytic degradation of Abeta. Neuron 58, 681-693. 
 32 
[61] Vance JE, Hayashi H (2010) Formation and function of apolipoprotein E-
containing lipoproteins in the nervous system. Biochim Biophys Acta 1801, 
806-818. 
[62] Kim WS, Bhatia S, Elliott DA, Agholme L, Kagedal K, McCann H, Halliday 
GM, Barnham KJ, Garner B (2010) Increased ATP-binding cassette 
transporter A1 expression in Alzheimer's disease hippocampal neurons. J 
Alzheimers Dis 21, 193-205. 
 
 
 33 
Supplementary Table 1. PCR primers  
_________________________________________________________________ ________ 
Gene  GenBank Primer 5’ – 3’ Product 
  accession Forward & Reverse  size (bp) 
____________________________________________________________________ _____ 
 
ABCA1  NM_005502  F AACTCTACATCTCCCTTCCCG      123 
  R CTCCTGTCGCATGTCACTCC 
 
AβPP NM_000484 F ACATGCACATGAATGTCCAG     169 
  R CACCAGTTCTGGATGGTCAC 
 
β-actin  NM_001101 F GAATTCTGGCCACGGCTGCTTCCAGCT     162 
  R AAGCTTTTTCGTGGATGCCACAGGACT  
______________________________________________________________________ ___ 
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FIGURE LEGENDS 
 
FIG. 1. Functional properties of wild type and mutant ABCA1. A, Schematic 
representation of ABCA1 protein structure and the position of Tangier disease 
missense mutations, NBD, nucleotide binding domain. B, Ability of wild type and 
mutant ABCA1 to stimulate cholesterol efflux to apoA-I. HEK293 cells were 
transfected with mock empty vector (M), wild type (WT), R587W (R), W590S (W) or 
Δ (Δ46) ABCA1, labeled with [3H]cholesterol, and then incubated with either bovine 
serum albumin (BSA) (light bars) or apoA-I (15 µg/ml) (dark bars). Data are mean 
values derived from triplicates with SE represented by the error bars, *p<0.05, ** 
p<0.01, *** p<0.001. C, Tabulated summary of the functional properties of wild type 
and mutant ABCA1. Data used to generate the table in are from previously published 
studies [24,25]. 
 
FIG. 2. Effect of wild type and mutant ABCA1 on AβPP processing. CHO-AβPP 
cells (stably expressing the human AβPP695) were transiently transfected with wild 
type (WT) and mutant ABCA1. The transfection efficiency of ABCA1 cDNAs was 
confirmed at the mRNA level by PCR amplification and agarose gel electrophoresis 
(A) and at the protein level by western blotting using anti-ABCA1 antibody (B). β-
actin was used as an internal control in both cases. The expression of the human 
AβPP695 in these transfected cells was measured at the mRNA level (A) and at the 
cellular protein level (D). The expression of secreted sAβPPα was also measured by 
western blotting (D). The signal intensity of the protein bands was quantified using 
ImageJ software (C, E). Mock empty vector (M), wild type (WT), R587W (R), 
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W590S (W), Δ46 (Δ). Data are mean values derived from triplicates with SE 
represented by the error bars, *p<0.05, ** p<0.01, *** p<0.001. 
  
FIG. 3. Impact of wild type and mutant ABCA1 on Aβ  peptide generation. CHO-
AβPP cells (stably expressing the human AβPP695) were transiently transfected with 
wild type (WT) and mutant ABCA1 and the secreted Aβ and cellular CTFβ were 
measured by western blotting (A, C). The signal intensity of the protein bands was 
quantified using ImageJ software (B, D). Mock empty vector (M), wild type (WT), 
R587W (R), W590S (W), Δ46 (Δ). Data are mean values derived from triplicates with 
SE represented by the error bars, *p<0.05, ** p<0.01, *** p<0.001. 
 
 FIG. 4. Impact of ABCA1 on AβPP localisation in lipid rafts. A, CHO-AβPP cells 
(stably expressing the human AβPP695) grown in 175 cm2 flasks were transiently 
transfected with mock empty vector or ABCA1 and the secreted Aβ and sAβPPα 
were measured by western blotting. B, The transfected cells were harvested and lipid 
raft (LR) and non-raft (NR) membrane fractions were isolated and probed with 
flotillin-2 (Flot) and calnexin (Clnx) antibodies to confirm the purity of the fractions. 
The expression of ABCA1 and AβPP was analysed by western blotting in the non raft 
(C) and lipid raft (D) fractions. Calnexin (Clnx) and flotillin-2 (Flot), respectively, 
were used as loading controls. E, The signal intensity of the protein bands was 
quantified using ImageJ software. Data are mean values derived from triplicates with 
SE represented by the error bars, ** p<0.01, *** p<0.001. 
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FIG. 5. Impact of ABCA1 on endogenous AβPP processing in human SK-N-SH 
neurons. A, SK-N-SH neuroblastoma cells grown in 175 cm2 flasks were transiently 
transfected with mock empty vector or ABCA1, the culture media concentrated and 
Aβ and sAβPPα measured by western blotting (see also Suppl Fig 2). B, The 
transfected cells were harvested and lipid raft (LR) and non-raft (NR) membrane 
fractions were isolated and probed with Gαi-2 and calnexin (Clnx) antibodies to 
confirm the purity of the fractions. The expression of ABCA1 and AβPP was 
analysed by western blotting in the non-raft (C) and lipid raft (D) fractions. Calnexin 
(Clnx) and Gai-2 respectively were used as loading controls. E, The signal intensity of 
the protein bands was quantified using ImageJ software. Data are mean values derived 
from triplicates with SE represented by the error bars, *p<0.05, ** p<0.01. 
 
FIG. 6. Analysis of AβPP dimerization and interaction with ABCA1. A, CHO-
AβPP cells were transiently transfected with wild type and mutant ABCA1 and 
protein lysates were subjected to non-reducing gel electrophoresis and western 
blotting with AβPP antibody. β-actin was used as a loading control. B, In a separate 
experiment, CHO-AβPP cells were transiently transfected with wild type and mutant 
ABCA1 and protein lysates were immunoprecipitated with anti-AβPP antibody and 
then probed with anti-ABCA1 antibody, stripped, and re-probed with anti-AβPP 
antibody. Mock empty vector (M), wild type (WT), R587W (R), W590S (W), Δ46 
(Δ). 
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SUPPLEMENTARY FIG. 1. Analysis of ABCA1 and AβPP proteins in lipid raft 
and non-raft membrane fractions. A, CHO-AβPP cells were transiently transfected 
with mock empty vector or ABCA1 and lipid raft and non-raft membrane fractions 
were isolated. Equal amounts of protein was loaded onto each well and analysed by 
western blotting with ABCA1 and AβPP antibodies. B, A longer exposure (3h) of 
film of the ABCA1 western blot was used to enhance the signal. 
 
SUPPLEMENTARY FIG. 2. Impact of ABCA1 on endogenous sAβPPα  
production by human SK-N-SH neurons. SK-N-SH neuroblastoma cells grown in 
175 cm2 flasks were transiently transfected with mock empty vector or ABCA1 and 
the culture media sAβPPα measured by western blotting. Western blotting of cell 
lysates for β-actin was used as a control for cellular protein levels. 
 
SUPPLEMENTARY FIG. 3. Impact of ABCA1 on γ-secretase and BACE1 
proteins in cell lysates and lipid raft membrane fractions. A, CHO-AβPP cells 
were transiently transfected with mock empty vector or ABCA1 and cell lysates (A) 
and lipid raft membrane fractions (B) were analysed for presenilin 1 (PS1), nicastrin 
(Nic.), BACE1 (BACE) by Western blotting as indicated. β-Actin and flotilin-2 
(Flot.) were used to confirm equal protein loading of the lysates and raft fractions, 
respectively. Quantification of the signal intensity relative to the relevant control 
proteins is shown in the histogram (C). Note we did not detect a reliable signal for 
BACE1 in the lipid raft membrane fractions in these experiments (not shown). Data 
are representative of two experiments performed in triplicate. **, p < 0.01. 
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